{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:33:15Z","timestamp":1791181995543,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.imlet.2007.02.003","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T17:46:45Z","timestamp":1172857605000},"page":"120-128","source":"Crossref","is-referenced-by-count":22,"title":["Inhibition of human cord blood-derived mast cell responses by anti-Fc\u025bRI mAb 15\/1 versus anti-IgE Omalizumab"],"prefix":"10.1016","volume":"109","author":[{"given":"Irina","family":"Mirkina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Schweighoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Kricek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2007.02.003_bib1","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.4049\/jimmunol.166.10.5979","article-title":"Kricek F: inhibition of antigen-induced mediator release from IgE-sensitized cells by a monoclonal anti-Fc epsilon RI alpha-chain receptor antibody: implications for the involvement of the membrane-proximal alpha-chain region in Fc epsilon RI-mediated cell activation","volume":"166","author":"Nechansky","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni1158","article-title":"Mast cells in the development of adaptive immune responses","volume":"6","author":"Galli","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4049\/jimmunol.174.1.507","article-title":"SHIP down-regulates FcepsilonR1-induced degranulation at supraoptimal IgE or antigen levels","volume":"174","author":"Gimborn","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2172-3-5","article-title":"Transcriptional response of human mast cells stimulated via the Fc(epsilon)RI and identification of mast cells as a source of IL-11","volume":"3","author":"Sayama","year":"2002","journal-title":"BMC Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-200161020-00008","article-title":"Omalizumab","volume":"61","author":"Easthope","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.imlet.2007.02.003_bib7","first-page":"81","article-title":"Technology evaluation: omalizumab, Genentech\/Novartis\/Tanox","volume":"5","author":"Lazaar","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.imlet.2007.02.003_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000070434","article-title":"Immunological and clinical changes in allergic asthmatics following treatment with omalizumab","volume":"131","author":"Noga","year":"2003","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000090387","article-title":"Effect of omalizumab on adenosine 5\u2032-monophosphate responsiveness in subjects with allergic asthma","volume":"139","author":"Prieto","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D30MC9C9TW","article-title":"Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody","volume":"11","author":"Scheinfeld","year":"2005","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.imlet.2007.02.003_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1024\/0040-5930.58.5.329","article-title":"Specific and nonspecific (anti-IgE) immunotherapy of allergic diseases","volume":"58","author":"Pichler","year":"2001","journal-title":"Ther Umsch"},{"key":"10.1016\/j.imlet.2007.02.003_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0014-5793(98)01558-0","article-title":"The membrane-proximal part of FcepsilonRIalpha contributes to human IgE and antibody binding\u2014implications for a general structural motif in Fc receptors","volume":"441","author":"Nechansky","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.imlet.2007.02.003_bib14","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1084\/jem.20030680","article-title":"Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis","volume":"199","author":"Jolly","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.imlet.2007.02.003_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-1759(02)00011-X","article-title":"The establishment of a combined serum-free and serum-supplemented culture method of obtaining functional cord blood-derived human mast cells","volume":"262","author":"Dahl","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.imlet.2007.02.003_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0145-2126(01)00030-3","article-title":"Mast cell lineage development and phenotypic regulation","volume":"25","author":"Austen","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.imlet.2007.02.003_bib17","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","article-title":"Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13)","volume":"94","author":"Kirshenbaum","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2007.02.003_bib18","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1046\/j.1365-2222.2002.01373.x","article-title":"Characterization of \u2019adult-type\u2019 mast cells derived from human bone marrow CD34(+) cells cultured in the presence of stem cell factor and interleukin-6. Interleukin-4 is not required for constitutive expression of CD54, Fc epsilon RI alpha and chymase, and CD13 expression is reduced during differentiation","volume":"32","author":"Shimizu","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.imlet.2007.02.003_bib19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/nature02991","article-title":"Essential role for the p110delta phosphoinositide 3-kinase in the allergic response","volume":"431","author":"Ali","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2007.02.003_bib20","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/j.jaci.2004.12.1124","article-title":"Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy","volume":"115","author":"Poole","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib21","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1146\/annurev.immunol.17.1.931","article-title":"The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology","volume":"17","author":"Kinet","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib22","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/intimm\/8.9.1367","article-title":"Induction of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells by IL-4","volume":"8","author":"Toru","year":"1996","journal-title":"Int Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0091-6749(98)70140-X","article-title":"Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells","volume":"102","author":"Toru","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.imlet.2007.02.003_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood.V91.1.187","article-title":"Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation","volume":"91","author":"Toru","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2007.02.003_bib25","doi-asserted-by":"crossref","first-page":"B24","DOI":"10.1038\/35037021","article-title":"Signalling through the high-affinity IgE receptor Fc epsilonRI","volume":"402","author":"Turner","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2007.02.003_bib26","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood.V99.11.4039","article-title":"Translocation of the tetraspanin CD63 in association with human eosinophil mediator release","volume":"99","author":"Mahmudi-Azer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2007.02.003_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1083\/jcb.200501111","article-title":"Fc{epsilon}RI-mediated mast cell degranulation requires calcium-independent microtubule-dependent translocation of granules to the plasma membrane","volume":"170","author":"Nishida","year":"2005","journal-title":"J Cell Biol"},{"key":"10.1016\/j.imlet.2007.02.003_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/sj.cr.7290301","article-title":"Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of igE-dependent upregulation","volume":"15","author":"Hennersdorf","year":"2005","journal-title":"Cell Res"},{"key":"10.1016\/j.imlet.2007.02.003_bib29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1398-9995.2006.00987.x","article-title":"Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation","volume":"61","author":"Nopp","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.imlet.2007.02.003_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1034\/j.1600-065X.2001.790108.x","article-title":"Variable expression of activation-linked surface antigens on human mast cells in health and disease","volume":"179","author":"Valent","year":"2001","journal-title":"Immunol Rev"},{"key":"10.1016\/j.imlet.2007.02.003_bib31","doi-asserted-by":"crossref","first-page":"14814","DOI":"10.1074\/jbc.M009851200","article-title":"Phosphoinositide 3-kinase facilitates antigen-stimulated Ca(2+) influx in RBL-2H3 mast cells via a phosphatidylinositol 3,4,5-trisphosphate-sensitive Ca(2+) entry mechanism","volume":"276","author":"Ching","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.imlet.2007.02.003_bib32","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2004-02-0631","article-title":"Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells","volume":"104","author":"Hundley","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2007.02.003_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jim.2005.06.008","article-title":"Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy","volume":"303","author":"Hamilton","year":"2005","journal-title":"J Immunol Methods"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247807000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247807000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T11:07:49Z","timestamp":1628507269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247807000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0165247807000314"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2007.02.003","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}